

**4<sup>th</sup> INTERNATIONAL CONFERENCE ON  
HEMATOLOGIC MALIGNANCIES AT OLDER AGE: BIOLOGY AND THERAPY**

Mandelieu Congress Center, Mandelieu, France

March 9-11, 2018

Chairs : Bob Löwenberg, Benjamin Ebert, Pierre Fenaux, Michael Hallek

**Friday, March 9, 2018**

**08:30–08:45 Welcome**

**SESSION I – Aging hematopoiesis**

Chair: Emmanuelle Passegué (New York)

08:45-09:00	HSCs and aging	Emmanuelle Passegué (New York)
09:00-09:05	<i>Discussion</i>	
09:05-09:20	Epigenetic stress response in stem cell aging	Karl Lenhard Rudolph (Leibniz)
09:20-09:25	<i>Discussion</i>	
09:25-09:40	Neogenin-1, a novel cell surface receptor involved in aging of hematopoietic stem cells	Gerald de Haan (Groningen)
09:40-09:45	<i>Discussion</i>	
09:45-10:00	DNA damage, a driving force of aging	Björn Schumacher (Cologne)
10:00-10:05	<i>Discussion</i>	
10:05-10:35	<i>Round table or short communications or controversial debates</i>	

**10:35-11:05 Coffee Break**

**SESSION II – Clonal hematopoiesis and aging**

Chair: Benjamin Ebert (Boston)

11:05-11:20	Clonal hematopoiesis	Benjamin Ebert (Boston)
11:20-11:25	<i>Discussion</i>	
11:25-11:40	Clonal hematopoiesis	George Vassiliou (Cambridge)
11:40-11:45	<i>Discussion</i>	
11:45-12:00	Selection of TP53 mutant clones following chemotherapy	Terrence N. Wong (St Louis)
12:00-12:05	<i>Discussion</i>	
12:05-12:35	<i>Round Table or short communications or controversial debate or Keynote</i>	

**12:35-13:45 Lunch**

### **SESSION III – The aging hematopoietic system**

Chair: Nancy Berliner (Boston)

13:45-14:00	The aging immune system	Emmanuelle Passegué (New York)
14:00-14:05	<i>Discussion</i>	
14:05-14:20	Aging HSC in primates	Cynthia Dunbar (Bethesda)
14:20-14:25	<i>Discussion</i>	
14:25-14:40	Aging stem cells	Michael Milsom (Heidelberg)
14:40-14:45	<i>Discussion</i>	
14:45-15:00	Anemia at older age	Nancy Berliner (Boston)
15:00-15:05	<i>Discussion</i>	
15:05-15:35	<i>Round table or short communications or controversial debate</i>	
<b>15:35-16:05</b>	<b><i>Coffee break</i></b>	

### **SESSION IV – MDS**

Chair: Pierre Fenaux (Paris)

16:05-16:20	Microenvironment and MDS	Rebekka Schneider (Rotterdam)
16:20-16:25	<i>Discussion</i>	
16:25-16:40	Biology of MDS	Benjamin Ebert (Boston)
16:40-16:45	<i>Discussion</i>	
16:45-17:00	Management of low grade MDS	Uwe Platzbecker (Dresden)
17:00-17:05	<i>Discussion</i>	
17:05-17:20	Management of high grade MDS	Pierre Fenaux (Paris)
17:20-17:25	<i>Discussion</i>	
17:25-17:40	Management of CMML and other MDS/MPN entities	Raphael Itzykson (Paris)
17:40-17:45	<i>Discussion</i>	
17:45-18:15	<i>Round Table</i>	
18:15-18:30	Assessing the aging individual with hematologic disorders:	Tanya Wildes (St Louis)
	How geriatric assessment can define the fitness of an older patient	
18:30-18:35	<i>Discussion</i>	
<b>18:35-20:05</b>	<b>Get Together and Manned Poster Session (stand up cocktails and buffet dinner for all)</b>	

**09:00-10:00 Simultaneous Meet the Expert Sessions**

- |  |                                |
|--|--------------------------------|
| 1. HSC's and aging   | Emmanuelle Passegué (New York) |
| 2. Aging and bone marrow failure                                   | Mick Milsom (Heidelberg)       |
| 3. New agents for myeloma and their utility in frontline treatment | Irene Ghobrial (Boston)        |

**10:00-10:30 Coffee break**

**SESSION V – Acute leukemia**

Chair: Bob Löwenberg (Rotterdam)

- |             |  |                               |
|-------------|--|-------------------------------|
| 10:30-10:45 | Biology of AML at older age  | Terrence N. Wong (St Louis)   |
| 10:45-10:50 | <i>Discussion</i>  |                               |
| 10:50-11:05 | Therapeutic management of the so-called “fit” older patient with AML | Bob Löwenberg (Rotterdam)     |
| 11:05-11:10 | <i>Discussion</i>  |                               |
| 11:10-11:25 | Management of the unfit patient with AML                             | Gert Ossenkoppele (Amsterdam) |
| 11:25-11:30 | <i>Discussion</i>  |                               |
| 11:30-11:45 | The older patient with ALL   | Hervé Dombret (Paris)         |
| 11:45-11:50 | <i>Discussion</i>  |                               |
| 11:50-12:05 | Alloegeneic stem cell transplantation at older age                   | Nicolaus Kröger (Hamburg)     |
| 12:05-12:10 | <i>Discussion</i>  |                               |
| 12:10-12:40 | <i>Round Table or short communications or controversial debate</i>   |                               |

**12:40-13:40 Lunch**

**SESSION VI – Multiple myeloma, precursor lesions and management questions in the elderly**

Chair: Jesus San Miguel (Pamplona)

- |             |  |                             |
|-------------|--|-----------------------------|
| 13:40-13:55 | Clonal evolution of multiple myeloma   | Nikhil Munshi (Boston)      |
| 13:55-14:00 | <i>Discussion</i>  |                             |
| 14:00-14:15 | MGUS and MGUS transition to myeloma, what do we need to do?  | Irene Ghobrial (Boston)     |
| 14:15-14:20 | <i>Discussion</i>  |                             |
| 14:20-14:35 | Multiple myeloma in the elderly, a particular challenge in light of numerous novel agents.                               | Jesus San Miguel (Pamplona) |
| 14:35-14:40 | <i>Discussion</i>  |                             |
| 14:40-14:55 | Autologous stem cell transplantation in the elderly patient with multiple myeloma. Do we still need it? Until which age? | Hermann Einsele (Würzburg)  |
| 14:55-15:00 | <i>Discussion</i>  |                             |
| 15:00-15:30 | <i>Round Table or short communications or controversial debate</i>   |                             |

**15:30-16:00**      *Coffee Break*

**SESSION VII – Lymphoma: clonal evolution and specific management strategies in the elderly**

Chair: Loretta J. Nastoupil (Houston)

16:00-16:15	Epigenetics and stem cell aging and hematologic malignancies	Maria Ken Figueroa (Miami)
16:15-16:20	<i>Discussion</i>	
16:20-16:35	Clonal evolution in malignant lymphoma	Jude Fitzgibbon (London)
16:35-16:40	<i>Discussion</i>	
16:40-16:55	Management of indolent lymphoma in the elderly patient	Umberto Vitolo (Turin)
16:55-17:00	<i>Discussion</i>	
17:00-17:15	Management of comorbidity and specific adverse events in the era of novel kinase inhibitors (ibrutinib, idelalisib, venetoclax) for lymphoid malignancies (e.g. bleeding, atrial fibrillation, ...)	Farrukh Awan (Columbus)
17:15-17:20	<i>Discussion</i>	
17:20-17:35	Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma	Loretta J. Nastoupil (Houston)
17:35-17:40	<i>Discussion</i>	
17:40-18:10	<i>Round Table</i>	

**Sunday, March 11, 2018**

**07:30-8:30**      **Simultaneous Meet the Expert Sessions**

1. DNA damage checkpoint and aging	Karl Lenhard Rudolph (Leibniz)
2. The patient presenting with neutropenia	Nancy Berliner (Boston)
3. Inherited myeloid neoplasms	Tom Vulliamy (London)
4. Frontline treatment in CLL	Valentin Goede (Cologne)

**SESSION VIII – CLL and MBL, molecular evolution, and specific management strategies in the elderly.**

Chair: Michael Hallek (Cologne)

08:45-09:00	Clonal evolution in CLL and monoclonal B-lymphocytosis	Dan-Avi Landau (New York)
09:00-09:05	<i>Discussion</i>	
09:05-09:20	Monoclonal B-lymphocytosis: frequency, clinical course and genetics of precursor lesions of CLL: the clinical relevance in the elderly patient	Andy Rawstron (Leeds)
09:20-09:25	<i>Discussion</i>	
09:25-09:40	Biology and management of CLL in the elderly	Valentin Goede (Cologne)
09:40-09:45	<i>Discussion</i>	
09:45-10:00	Richter transformation in the elderly patient: molecular origin and new strategies for improved therapies	Davide Rossi (Bellinzona)
10:00-10:05	<i>Discussion</i>	

10:05-10:35 *Round Table or short communications or controversial debates*

**10:35-11:05** *Coffee Break*

**SESSION IX – Lymphoma of high-risk phenotype: molecular characterization and optimal management.**

Chair: Michael Hallek (Cologne)

11:05-11:20 Targeting the DNA Damage Response in high-risk lymphoma: Christian Reinhardt (Cologne)  
biology and insights for future, less toxic approaches of therapy

11:20-11:25 *Discussion*

11:25-11:40 Double hit and other types of high-risk lymphoma: Paul Hamlin (New York)  
molecular features and optimal management in the elderly patient

11:40-11:45 *Discussion*

11:45-12:00 T-cell lymphoma in the elderly: do we have novel agents? Pier Luigi Zinzani (Bologna)  
What is the optimal treatment strategy?

12:00-12:05 *Discussion*

12:05-12:20 CNS lymphoma in the elderly: which strategy for which Gerald Illerhaus (Stuttgart)  
patient?

12:20-12:25 *Discussion*

12:25-12:55 *Round table and controversial debates: high risk lymphoma in the elderly? When do we start, when do we stop therapy?*

**12:55-13:00** *Closing Remarks*

**MEETING CLOSURE**